Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.

Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ.

Br J Ophthalmol. 2012 Dec;96(12):1469-73. doi: 10.1136/bjophthalmol-2012-302167.

PMID:
23001255
2.

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.

Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M.

Retina. 2009 Mar;29(3):329-34. doi: 10.1097/IAE.0b013e31819093e6.

PMID:
19092732
3.

Bimonthly ranibizumab for neovascular age-related macular degeneration.

Cohen SY, Maloberti B, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Grenet T, Quentel G.

Ophthalmologica. 2014;231(2):80-5. doi: 10.1159/000356401.

PMID:
24356074
4.

Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.

Ladas ID, Chatziralli IP, Kotsolis AI, Douvali M, Georgalas I, Theodossiadis PG, Rouvas AA.

Ophthalmologica. 2012;228(2):93-101. doi: 10.1159/000337347.

PMID:
22571933
5.

Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.

Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M.

Invest Ophthalmol Vis Sci. 2011 Jul 1;52(7):4694-702. doi: 10.1167/iovs.10-6080.

PMID:
21282580
6.

Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection.

Sayed KM, Naito T, Nagasawa T, Katome T, Mitamura Y.

Graefes Arch Clin Exp Ophthalmol. 2011 Oct;249(10):1449-58. doi: 10.1007/s00417-011-1672-2.

PMID:
21494878
7.
8.

A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD.

Roberts P, Mittermueller TJ, Montuoro A, Sulzbacher F, Munk M, Sacu S, Schmidt-Erfurth U.

Invest Ophthalmol Vis Sci. 2014 Sep 4;55(10):6623-30. doi: 10.1167/iovs.14-14293.

PMID:
25190663
9.

Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.

Saito M, Iida T, Kano M.

Retina. 2012 Jul;32(7):1250-9. doi: 10.1097/IAE.0b013e318236e503.

PMID:
22446886
10.

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.

Cunningham ET Jr, Feiner L, Chung C, Tuomi L, Ehrlich JS.

Ophthalmology. 2011 Dec;118(12):2447-52. doi: 10.1016/j.ophtha.2011.05.026.

PMID:
21872935
11.

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.

Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.

Ophthalmology. 2009 Sep;116(9):1755-61. doi: 10.1016/j.ophtha.2009.03.017.

PMID:
19560206
12.

One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.

Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O.

Retina. 2011 Jul-Aug;31(7):1261-7. doi: 10.1097/IAE.0b013e318207d152.

PMID:
21499194
13.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010.

PMID:
22465368
14.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.

Ophthalmology. 2006 Apr;113(4):633.e1-4.

PMID:
16483659
15.

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3.

PMID:
19404661
16.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
17.

Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.

Chang LK, Spaide RF, Klancnik JM, Sorenson J, Slakter JS, Freund KB, Yannuzzi LA, Tseng JJ, Klein R.

Retina. 2011 May;31(5):821-8. doi: 10.1097/IAE.0b013e3181feccc0.

PMID:
21317833
18.

Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).

Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; MONET Clinical Study Group..

Ophthalmology. 2012 Sep;119(9):1867-73. doi: 10.1016/j.ophtha.2012.03.043.

PMID:
22683252
19.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022.

PMID:
22551738
20.

Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Lai TY, Chan WM, Liu DT, Lam DS.

Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1877-80.

PMID:
17901972
Items per page

Supplemental Content

Support Center